Nationwide evaluation of acute kidney injury in hospitalized patients in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the burden of acute kidney injury (AKI) among hospitalized patients in China from 2011 to 2016. By analyzing changes in serum creatinine levels based on the 2012 Kidney Disease Improving Global Outcomes (KDIGO) criteria, the study seeks to identify the prevalence and risk factors associated with AKI. The data will be collected from a nationwide cohort of patients, providing valuable insights into the epidemiology of this condition in the Chinese healthcare context.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patients diagnosed on the basis of changes in serum creatinine according to the criteria of 2012 Kidney Disease Improving Global Outcomes(KDIGO)

Exclusion Criteria:

* Serum creatinine record less than two times during hospitalization
* Patients being diagnosed with End-stage kidney disease (chronic kidney disease stage 5)
* Nephrectomy
* Kidney transplantation
* Peak serum creatinine of less than 53µ mol/L
* Serum creatinine decrease after amputation

Where it's running

• Nephrology Dept,Guangdong General Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Liang Xinling, M.D.,Ph.D — Nephrology Dept,Guangdong General Hospital
• Study coordinator: Liang Xinling, M.D.,Ph.D
• Email: xinlingliang@139.com
• Phone: 13808819770

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Remote Ischemic Preconditioning at Different Times After Heart Valve Surgery

  This study tests whether applying brief, controlled blood-flow restrictions to a limb at different times after heart valve surgery can help protect organs and reduce complications like kidney injury.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07888634

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Biomarkers to predict CSA-AKI risk before heart surgery

  This study tests new biomarkers to see if they can predict CSA-AKI risk in adults undergoing cardiovascular surgery.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07811570

• Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter

  This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07807410

• Perioperative GFR Monitoring to Predict CSA-AKI and CA-AKI

  This study tests whether perioperative transcutaneous fluorescence GFR measurements can predict CSA-AKI or CA-AKI in adults undergoing cardiovascular procedures or iodine contrast exposure.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07749417

• Restarting RAS inhibitors after AKI: a quick test in hospitalized adults

  This pilot study tests whether restarting renin-angiotensin system inhibitors early after acute kidney injury is feasible and safe in hospitalized adults already using these medicines.

  Recruiting Phase 4 University of California, San Francisco · San Francisco, California · NCT07734636

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.